

# Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling

Eileen Miller, Alicja Czopek, Karolina M. Duthie, Nicholas S. Kirkby, Elisabeth E. Fransen van de Putte, Sibylle Christen, Robert A. Kimmitt, Rebecca Moorhouse, Raphael F.P. Castellán, Yuri V. Kotelevtsev, Rhoda E. Kuc, Anthony P. Davenport, Neeraj Dhaun, David J. Webb, Patrick W.F. Hadoke

**Abstract**—The role of smooth muscle endothelin<sub>B</sub> (ET<sub>B</sub>) receptors in regulating vascular function, blood pressure (BP), and neointimal remodeling has not been established. Selective knockout mice were generated to address the hypothesis that loss of smooth muscle ET<sub>B</sub> receptors would reduce BP, alter vascular contractility, and inhibit neointimal remodeling. ET<sub>B</sub> receptors were selectively deleted from smooth muscle by crossing floxed ET<sub>B</sub> mice with those expressing cre-recombinase controlled by the transgelin promoter. Functional consequences of ET<sub>B</sub> deletion were assessed using myography. BP was measured by telemetry, and neointimal lesion formation induced by femoral artery injury. Lesion size and composition (day 28) were analyzed using optical projection tomography, histology, and immunohistochemistry. Selective deletion of ET<sub>B</sub> was confirmed by genotyping, autoradiography, polymerase chain reaction, and immunohistochemistry. ET<sub>B</sub>-mediated contraction was reduced in trachea, but abolished from mesenteric veins, of knockout mice. Induction of ET<sub>B</sub>-mediated contraction in mesenteric arteries was also abolished in these mice. Femoral artery function was unaltered, and baseline BP modestly elevated in smooth muscle ET<sub>B</sub> knockout compared with controls ( $+4.2 \pm 0.2$  mmHg;  $P < 0.0001$ ), but salt-induced and ET<sub>B</sub> blockade-mediated hypertension were unaltered. Circulating endothelin-1 was not altered in knockout mice. ET<sub>B</sub>-mediated contraction was not induced in femoral arteries by incubation in culture medium or lesion formation, and lesion size was not altered in smooth muscle ET<sub>B</sub> knockout mice. In the absence of other pathology, ET<sub>B</sub> receptors in vascular smooth muscle make a small but significant contribution to ET<sub>B</sub>-dependent regulation of BP. These ET<sub>B</sub> receptors have no effect on vascular contraction or neointimal remodeling. (*Hypertension*. 2017;69:275-285. DOI: 10.1161/HYPERTENSIONAHA.115.07031.) • [Online Data Supplement](#)

**Key Words:** autoradiography ■ endothelin-1 ■ hypertension ■ neointima ■ vasoconstriction

Endothelin-1 (ET-1), released by vascular endothelial cell (EC) and inner medullary collecting duct cells (and other cells under pathological conditions), stimulates endothelin<sub>A</sub> (ET<sub>A</sub>) and endothelin<sub>B</sub> (ET<sub>B</sub>) receptor subtypes.<sup>1,2</sup> ET<sub>A</sub> are present on vascular smooth muscle cells (VSMCs), predominantly mediating contraction<sup>3</sup> and regulating blood pressure (BP).<sup>4</sup> They also influence mitogenesis,<sup>5</sup> generation of reactive oxygen species, and adhesion molecule expression.<sup>6,7</sup> ET<sub>A</sub> receptors on leucocytes mediate cytokine release and cellular chemotaxis.<sup>8</sup> Many of these processes contribute to vascular

remodeling, and ET-1 clearly drives arterial lesion formation (including neointimal proliferation after injury).<sup>7</sup> This can be inhibited by selective ET<sub>A</sub> antagonism.<sup>9,10</sup>

Regulation of arterial function, BP, and arterial lesion formation by ET<sub>B</sub> receptors is likely to be more complex because they are expressed in EC, VSMC, and the kidney where they mediate physiologically antagonistic responses. ECET<sub>B</sub> receptors mediate production of vasodilator, antiproliferative, and anti-inflammatory molecules (eg, nitric oxide [NO])<sup>11,12</sup>; clearance of ET-1 from the circulation<sup>13,14</sup>; and regrowth of damaged

Received December 18, 2015; first decision January 2, 2016; revision accepted November 30, 2016.

From the University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (E.M., A.C., K.M.D., N.S.K., E.E.F.v.d.P., R.A.K., R.M., R.F.P.C., N.D., D.J.W., P.W.F.H.); University of Basel, Switzerland (S.C.); Centre for Functional Genomics, Skolkovo Institute of Science and Technology, Russian Federation (Y.V.K.); and Division of Experimental Medicine and Immunotherapeutics, Addenbrooke's Hospital, Cambridge, United Kingdom (R.E.K., A.P.D.).

Current address for N.S. Kirkby: National Heart and Lung Institute, Imperial College London, United Kingdom.

Current address for E.E.F. van de Putte: Department of Surgical Oncology, Division of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.115.07031/-/DC1>.

Correspondence to Patrick W.F. Hadoke, University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, United Kingdom. E-mail Patrick.Hadoke@ed.ac.uk

© 2016 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.115.07031

EC.<sup>15</sup> VSMC ET<sub>B</sub> can mediate vascular contraction, similar to the ET<sub>A</sub> subtype,<sup>16</sup> and may compensate for ET<sub>A</sub> receptor dysfunction.<sup>17</sup> ET<sub>B</sub> upregulation in VSMC may mediate vasoconstriction and proliferation in cardiovascular disease.<sup>18,19</sup>

ET<sub>B</sub>-dependent regulation of BP is demonstrated by the sustained hypertension caused by ET<sub>B</sub> receptor antagonism in mice.<sup>20</sup> The importance of receptor distribution in this response is indicated by increased BP after deletion of ET<sub>B</sub> receptors in the renal collecting duct<sup>21</sup> but not after deletion of ECET<sub>B</sub>.<sup>22</sup> The influence of VSMC ET<sub>B</sub> on BP has not been established but, given their potential to mediate vasoconstriction, deletion or antagonism of VSMC ET<sub>B</sub> would be predicted to reduce BP.

Despite the influence of ET-1 in vascular remodeling,<sup>23</sup> the role of ET<sub>B</sub> is less clear. ET<sub>B</sub> activation in EC (NO release) and kidney (reduced BP) would be predicted to inhibit arterial remodeling, thus favoring selective ET<sub>A</sub> antagonism for reducing neointimal proliferation.<sup>9</sup> Certainly, global deletion of ET<sub>B</sub> receptors increases vascular lesion size.<sup>10,24</sup> However, selective ECET<sub>B</sub> deletion did not influence lesion formation, suggesting that the protective role was mediated by ET<sub>B</sub> receptors in other tissues.<sup>9</sup> If ET<sub>B</sub> receptors in VSMC contribute to lesion formation, mixed ET<sub>A/B</sub> antagonists might have advantages over ET<sub>A</sub> selective compounds, although recent investigations<sup>9,10,24</sup> favor the latter.

We generated novel smooth muscle ET<sub>B</sub> receptor knockout (SMET<sub>B</sub> KO) mice to address the hypothesis that loss of these receptors would impair arterial contraction, lower BP, and reduce neointimal lesion formation in response to vascular injury.

## Methods

Mice with VSMC-selective ET<sub>B</sub> receptor deletion were generated by crossing homozygous floxed ET<sub>B</sub> mice with SM22cre transgenic mice, which express cre-recombinase in the heart and smooth muscle, (then backcrossed to a C57Bl/6J background for 4–6 generations), as described for ECET<sub>B</sub> KO.<sup>22</sup> Controls were Cre-negative littermates (ET<sub>B</sub><sup>fl/fl</sup>). Genotyping was performed using ear clips.<sup>22,25</sup> Wild-type (WT) C57Bl/6J mice were from Charles River (United Kingdom). Mice were housed according to the UK Home Office recommendations (22°C; 12-hour light/dark cycles) with free access to water and chow. Procedures were performed under the provisions of the Animals Scientific Procedures Act (1986) and approved by the local Ethics Committee.

Selective SMET<sub>B</sub> deletion was demonstrated in organs and in isolated aortic smooth muscle cells (SMCs) using polymerase chain reaction, autoradiography,<sup>14,26</sup> immunohistochemistry,<sup>27</sup> and functional (myographic) investigation of isolated trachea, arteries, and veins.<sup>28,29</sup>

The impact of SMET<sub>B</sub> KO on BP was assessed using radiotelemetry<sup>22</sup> in conscious, unrestrained male SMET<sub>B</sub> KO mice and age-matched controls (n=8 per group), fed on chow (7 days), high (7.6%) salt diet (7 days), then high salt plus ET<sub>B</sub> antagonist (SB192621; 30 mg<sup>-1</sup> kg<sup>-1</sup> day<sup>-1</sup> in drinking water, 7 days). ET-1 concentrations in plasma from WT C57Bl/6J, controls, and SMET<sub>B</sub> KO were measured after exposure to chow or to high salt diet plus ET<sub>B</sub> antagonist, by ELISA (Endothelin-1 Quantikine ELISA kit; R&D Systems, Oxford, United Kingdom).

Intraluminal (left) or nondenuding (right) femoral artery injury was achieved by insertion of an angioplasty guidewire or ligation, respectively, as described.<sup>9</sup> After 28 days, arteries were retrieved (after perfusion fixation) and analyzed using optical projection tomography, histology, and immunohistochemistry.<sup>9,30</sup>

## Statistics

Results are mean±SEM, for n mice. Group sizes were chosen to detect 5%, 20%, and 20% differences in BP (n=7), lesion size (n=7), and

maximum responses to vasoactive agents (n=6) with >90% power. Investigations were performed by operators blinded to treatment. Components of lesions were expressed as a percentage of the neointimal area. Analyses were performed with GraphPad Prism using Student *t* test, 1-way or 2-way ANOVA with a Tukey post hoc test, as indicated. Significance was assumed for *P*<0.05.

Detailed methods are in the [online-only Data Supplement](#).

## Results

### Identification of SMET<sub>B</sub> KO

Genotyping for SM22cre, WT, and delta band alleles (Figure 1A) identified SMET<sub>B</sub> KO (positive for SM22cre, floxed, and delta band and negative for WT allele) and controls (SMET<sub>B</sub><sup>fl/fl</sup> cre-negative littermates; negative for WT allele, positive for floxed allele, and negative for SM22cre and delta band). SMC isolated from the aorta of SMET<sub>B</sub> KO mice expressed the cre, delta, and flox bands, whereas controls did not express the cre and the delta bands (Figure 1B).

Autoradiography (Figure 1C) identified ET<sub>B</sub> receptors in the gut lining, lung, and kidney. This signal was not diminished after SMET<sub>B</sub> deletion. ET<sub>B</sub> expression (real-time polymerase chain reaction) was not altered in the colon, heart, or gastrocnemius muscle of SMET<sub>B</sub> KO mice (Figure S1 in the [online-only Data Supplement](#)). Confocal imaging of immunofluorescence (Figure 1D) clearly showed ET<sub>B</sub> receptors localizing to the endothelium (von Willebrand factor positive) in SMET<sub>B</sub> KO coronary artery. ET<sub>B</sub> staining in medial SM remained at background levels. This confirms maintained ET<sub>B</sub> receptor expression in the endothelium of SMET<sub>B</sub> KO mice.

### Functional Confirmation of SMET<sub>B</sub> KO

SMET<sub>B</sub> KO mice were healthy with normal body and organ weights (Table S1).


Sarafotoxin S6c (S6c)-mediated contraction in tracheas (which express ET<sub>B</sub> receptors on SM)<sup>22</sup> from controls was abolished by incubation with the selective ET<sub>B</sub> antagonist A192621 (Figure 2A).<sup>22</sup> In SMET<sub>B</sub> KO mice, S6c-mediated contraction was reduced (≈30%), but not abolished. The residual contraction was blocked by ET<sub>B</sub> antagonism. S6c-mediated contraction of mesenteric veins was abolished by selective deletion of SMET<sub>B</sub> (Figure 2B).

### SMET<sub>B</sub> KO and BP

Control and SMET<sub>B</sub> KO mice demonstrated a clear diurnal rhythm in BP (Figure 3A). Mean 24-hour BP was higher in SMET<sub>B</sub> KO mice than in controls (107.1±0.3 versus 102.8±0.5 mmHg; n=7; *P*<0.0001; Figure 3B). Systolic BP was not different between groups (123.5±0.6 versus 124.8±0.5 mmHg; *P*=0.09; Figure 3C), but SMET<sub>B</sub> KO mice had an increased diastolic BP (98.2±0.3 versus 92.2±0.4 mmHg; *P*<0.0001; Figure 3D). BP elevation occurred despite reduced heart rate (515±3 versus 538±5 bpm; *P*=0.004; Figure 3E). High salt increased BP in controls with a further increase induced by ET<sub>B</sub> antagonism (Figure 4A). These responses were similar in SMET<sub>B</sub> KO.

### SMET<sub>B</sub> KO and Circulating ET-1

Plasma ET-1 concentrations were similar in SMET<sub>B</sub> KO and control mice (Figure 4B) and consistent with levels in WT C57Bl/6J (1.14±0.08; n=6). The combination of high salt diet



**Figure 1.** Selective endothelin<sub>B</sub> ( $ET_B$ ) receptor deletion from smooth muscle. **A**, Mice were genotyped for (i) SM22cre (band at 500 bp), (ii) wild-type (band a 500 bp), and (iii) flox (band at 1171 bp)/delta (band at 259 bp) alleles in ear clip DNA. (i) Samples 1 and 2 are cre-positive, (ii) sample 4 is positive for the wild-type allele; samples 3 and 5 are not, (iii) samples 7 and 8 are positive for both the flox (*Continued*)



**Figure 1 Continued.** and the delta band; sample 6 has only the flox band. **B**, Polymerase chain reaction (PCR) for cre and flox/delta bands in murine aortic smooth muscle cells isolated from smooth muscle  $ET_B$  receptor knockout (SMET<sub>B</sub> KO) and control (C) mice. Control mice lacked cre and delta alleles, whereas SMET<sub>B</sub> KO expressed all 3. Standard DNA ladders have band sizes 1500–100 bp. **C**, Autoradiography showing maintained  $ET_B$  ligand binding in SMET<sub>B</sub> KO lung and kidney (representative of  $n=3$  mice/genotype). **D**, Confocal images of a coronary artery from an SMET<sub>B</sub> KO mouse stained for (i)  $ET_B$  receptor (green) or (ii) the endothelial cell marker von Willebrand factor (vWF; red). Merged images (iii) show clear colocalization of  $ET_B$  with the endothelium (arrows). There is no  $ET_B$  staining in medial smooth muscle. Scale bar=50  $\mu$ m. +Ve, positive control; –Ve, negative control;  $ET_A$  indicates endothelin<sub>A</sub>; H, heart; K, kidney; L, liver; Lu, lung; and NSB, nonspecific binding.

and  $ET_B$  antagonism increased plasma ET-1 to a similar extent in control-type and SMET<sub>B</sub> KO mice (Figure 4C).

### SMET<sub>B</sub> KO and Neointimal Remodeling

Wire injury of the left femoral artery generated neointimal lesions (Figure 5A).<sup>9</sup> Optical projection tomography demonstrated that SMET<sub>B</sub> KO altered neither the lesion volume (Figure 5B) nor cross-sectional narrowing (Figure 5C). Histological analysis showed a trend toward reduced cross-sectional narrowing in SMET<sub>B</sub> KO (Figure 5D). Ligation of the right femoral artery generated lesions<sup>9</sup> with similar volume

(Figure 5E) and maximal cross-sectional area (Figure 5F) in SMET<sub>B</sub> KO mice and control mice.

Immunohistochemistry (Figure S2) showed that SMET<sub>B</sub> KO did not differ from controls in the amount of macrophage (Mac-2; SMET<sub>B</sub> KO  $2.7\pm0.9\%$  versus Control  $2.6\pm0.7\%$  lesion area),  $\alpha$ -smooth muscle actin (SMET<sub>B</sub> KO  $14.8\pm4.1\%$  versus Control  $19.9\pm3.8\%$  lesion area), or collagen (SMET<sub>B</sub> KO  $9.7\pm3.1\%$  versus Control  $14.9\pm3.2\%$  lesion area) staining in the neointimal lesions.

### SMET<sub>B</sub> KO and Vascular Reactivity

In WT C57Bl/6J mice, EC removal from aortic rings abolished acetylcholine-mediated relaxation and enhanced the contractile response to phenylephrine but not to ET-1. EC removal from femoral arteries also abolished acetylcholine-mediated relaxation but had no effect on phenylephrine or ET-1 (Figure S3; Table S2). SMET<sub>B</sub> KO had no effect on contractile responses to phenylephrine or ET-1, or acetylcholine-mediated relaxation in femoral arteries (Figure S4; Table S3).


### Induction of $ET_B$ -Mediated Contraction in Isolated Mesenteric Arteries

ET-1-mediated contraction in mesenteric arteries from WT C57Bl/6J mice was shifted to the right by mixed  $ET_{A/B}$ , or selective  $ET_A$ , antagonism, but not by  $ET_B$  selective antagonism (Figure S5; Table S4). Unlike mesenteric veins (Figure 6A), mesenteric arteries freshly isolated from WT C57Bl/6J mice did not contract in response to S6c (Figure 6B).


Incubation in culture medium ( $\leq 5$  days) can induce  $ET_B$ -mediated contraction in rat arteries.<sup>29</sup> Incubation of C57Bl/6J mesenteric veins in culture medium had no effect on S6c-mediated contraction (Figure 6A). In mesenteric arteries, incubation in culture medium selectively increased the contractile response to ET-1 (Table S5). Strikingly, S6c-mediated contraction was induced in isolated mesenteric arteries after incubation in culture medium (Figure 6B; Table S5), a response abolished by selective  $ET_B$ , or mixed  $ET_{A/B}$ , antagonism, but not by selective  $ET_A$  antagonism (Figure 6C; Table S6). Incubation of mesenteric arteries from SMET<sub>B</sub> KO mice in culture medium did not induce S6c-mediated contraction (Figure 6D).

### No Induction of $ET_B$ -Mediated Contraction in Femoral Arteries

S6c-mediated contraction was variable in femoral arteries from WT C57Bl/6J mice: some contracted but others did not (Figure 6E). Neither incubation of femoral arteries in culture medium (24 hours; Figure 6F) nor lesion formation induced S6c-mediated contraction; femoral arteries isolated 28 days after ligation contracted in response to ET-1 (Figure 6G) but not to S6c (Figure 6H). Responses to acetylcholine, sodium



**Figure 2.** Functional consequences of selective endothelin<sub>B</sub> ( $ET_B$ ) deletion from smooth muscle (SM). **A**, Sarafotoxin S6c (S6c)-induced contraction of isolated trachea was abolished by  $ET_B$  receptor antagonism (A192621; 100 nmol/L) but only reduced by selective smooth muscle  $ET_B$  receptor (SMET<sub>B</sub>) deletion (residual contraction was blocked by A192621). Columns are mean $\pm$ SEM ( $n=4$ ). \* $P<0.02$ , \*\* $P<0.005$ . **B**, S6c-induced contraction in murine mesenteric veins was abolished by SMET<sub>B</sub> deletion. Symbols represent mean $\pm$ SEM ( $n=4$ ). \* $P<0.05$ , \*\* $P<0.01$ . KO indicates knockout; and KPSS, potassium physiological salt solution.



**Figure 3.** Selective deletion of endothelin<sub>B</sub> (ET<sub>B</sub>) receptors from smooth muscle increases baseline blood pressure (BP). **A**, BP, assessed in conscious, unrestrained male smooth muscle ET<sub>B</sub> receptor knockout (SMET<sub>B</sub> KO) mice and controls (n=8 per group) using radiotelemetry, demonstrated a clear diurnal rhythm. Mean blood pressure (MBP) in SMET<sub>B</sub> KO (filled symbols) mice was consistently higher than controls (open symbols). **B**, Data averaged over 24 h confirmed elevated MBP in SMET<sub>B</sub> KO, with no difference in **(C)** systolic blood pressure (SBP) but **(D)** elevated diastolic blood pressure (DBP). **E**, Increased MBP was accompanied by reduced heart rate. Data are mean±SEM (n=8 per group). \*\**P*<0.005, \*\*\**P*<0.0001. D indicates day; and N, night.


nitroprusside, and phenylephrine were unaltered by lesion formation (Figure S6).

### Discussion

Tissue-specific knockout mice were generated to address the hypothesis that selective deletion of ET<sub>B</sub> receptors from VSMC would impair arterial contraction, lower BP, and reduce neointimal lesion size. SMET<sub>B</sub> KO attenuated S6c-mediated vascular and tracheal contraction, without altering other functional responses, but produced a modest (≈4

mm Hg) increase in BP. ET<sub>B</sub>-mediated contraction was not induced in femoral arteries after ligation, although injury-induced intimal lesion formation was unaffected by SMET<sub>B</sub> KO. Key findings are summarized (Figure S7) and compared with the ECET<sub>B</sub> KO (Table S7).


SMET<sub>B</sub> KO was based on our generation of ECET<sub>B</sub> KO,<sup>22</sup> crossing mice expressing Cre-recombinase controlled by the SM-specific SM22 promoter<sup>25</sup> with those bearing a floxed ET<sub>B</sub> gene.<sup>22</sup> This strategy was used to produce mice with SM-selective ET<sub>A</sub> deletion,<sup>4</sup> and renal collecting duct-selective



**Figure 4.** Selective deletion of endothelin<sub>B</sub> (ET<sub>B</sub>) receptors from smooth muscle does not alter blood pressure (BP) responses. **A**, BP, assessed in conscious, unrestrained male smooth muscle ET<sub>B</sub> receptor knockout (SMET<sub>B</sub> KO) mice and controls (n=8 per group) using radiotelemetry (i) was elevated by high salt diet (HS; 7 d) and by ET<sub>B</sub> antagonism (A192621; 30 mg<sup>-1</sup> kg<sup>-1</sup> d<sup>-1</sup>; 7 d) in both groups. (ii) Comparison of BP (averaged over 24 h) demonstrates the elevation in mean blood pressure (MBP) in response to high salt diet and high salt diet plus A192621. (iii) There was no difference in systolic blood pressure (SBP) in control compared with SMET<sub>B</sub> KO mice but (iv) diastolic blood pressure (DBP) was higher in SMET<sub>B</sub> KO for all treatment groups. **B**, Plasma endothelin-1 (ET-1) concentrations were similar in SMET<sub>B</sub> KO and controls and consistent with wild-type C57Bl/6J mice (1.14±0.08 pg/mL; n=6). ET-1 concentrations were elevated in control and SMET<sub>B</sub> KO mice after exposure to a high salt diet plus A192621. Data (mean±SEM) were analyzed using 2-way ANOVA with Tukey or Bonferroni post hoc test, as appropriate. **A**, \*P<0.05, \*\*P<0.01 compared with controls. **B**, \*\*\*\*P<0.00001 (effect of diet).

ET<sub>B</sub> deletion.<sup>21</sup> It has also been used within our group to produce mice with SM-selective deletion of glucocorticoid receptor<sup>31</sup> or 11β-hydroxysteroid dehydrogenase 1<sup>32</sup> (with LacZ staining in Rosa26 reporter mice showing SM22cre expression in the blood vessels and heart but not in the brain, kidney, or adrenal gland). As with ECET<sub>B</sub> KO,<sup>22</sup> SMET<sub>B</sub> KO mice were healthy. This contrasts with global ET<sub>B</sub> deletion, which causes coat spotting and death from megacolon,<sup>33</sup> requiring transgenic ET<sub>B</sub> rescue in the enteric nervous system.<sup>34</sup> Autoradiographic


detection of ET<sub>B</sub> receptors in lungs of SMET<sub>B</sub> KO mice indicates maintained expression in EC (which was lost in ECET<sub>B</sub> KO).<sup>14</sup> This was supported by colocalization of immunoreactivity for ET<sub>B</sub> with an EC marker (von Willebrand factor) in coronary arteries; absence of medial ET<sub>B</sub> staining was consistent with deletion from SMCs. Polymerase chain reaction confirmed that ET<sub>B</sub> had been deleted from aortic smooth muscle but not from heart, colon, or skeletal muscle (although direct evidence of ET<sub>B</sub> deletion from tracheal, mesenteric vein,



**Figure 5.** Selective smooth muscle endothelin<sub>B</sub> (SMET<sub>B</sub>) deletion does not alter neointimal lesion formation. **A**, Wire injury–induced lesion formation in femoral arteries from control and SMET<sub>B</sub> knockout (KO) mice. Neointimal lesion volume (**B**) and maximal cross-sectional area (**C**) were similar in control and SMET<sub>B</sub> KO mice when measured by optical projection tomography. Similar results were obtained when maximal cross-sectional area was measured histologically (**D**). Volume (**E**) and maximal cross-sectional area (**F**) of lesions induced by ligation were similar in control and SMET<sub>B</sub> KO mice (optical projection tomography [OPT]). Data are mean±SEM (n=7). EEL indicates external elastic lamina; IEL, internal elastic lamina; L, lumen; and NI, neointima.

mesenteric, or femoral artery smooth muscle was not obtained using this technique). Functional investigations confirmed that SMET<sub>B</sub>-dependent responses were lost in the knockout,

with the abolition of S6c-mediated contraction in mesenteric veins. Furthermore, induction of S6c-mediated contraction in mesenteric arteries incubated in culture medium (as in rat



**Figure 6.** Impact of smooth muscle endothelin<sub>B</sub> (SMET<sub>B</sub>) receptors on vascular function. **A**, Sarafotoxin S6c (S6c)-induced contraction in mesenteric veins (n=6) was not increased by incubation for 1 (n=3) or 5 (n=1) d in culture. **B**, Freshly isolated mesenteric arteries (n=6) did not respond to S6c, but contractions were induced by incubation in culture medium for 1 (n=7) or 5 (n=3) \*P<0.05, (Continued)



**Figure 6 Continued.** \*\* $P < 0.01$ , \*\*\* $P < 0.005$  compared with d 0. **C**, S6c-mediated contraction of mesenteric arteries after 24 h in culture ( $n = 7$ ) was abolished by ET<sub>B</sub> selective (A192621; 100 nmol/L;  $n = 3$ ) or mixed ET<sub>A/B</sub> (BQ-123+A192621;  $n = 3$ ) antagonism, but not by ET<sub>A</sub> receptor antagonism (BQ-123; 100 nmol/L;  $n = 3$ ); \*\* $P < 0.01$ , \*\*\* $P < 0.005$  compared with ET<sub>B</sub> or ET<sub>A/B</sub> antagonism; # $P < 0.05$ , ### $P < 0.005$  compared with vehicle. **D**, In contrast to controls ( $n = 4$ ), S6c-mediated, A192621 (100 nmol/L)-sensitive contraction was not induced in mesenteric arteries from SMET<sub>B</sub> knockout (KO) mice ( $n = 4$ ) by incubation in culture medium (24 h); \*\*\* $P < 0.005$ , \*\*\*\* $P < 0.001$  compared with antagonists. **E**, Contractile responses to S6c were unreliable in femoral arteries—some failed to contract, whereas others produced small contractions. \* $P < 0.05$ , \*\*\* $P < 0.005$ , \*\*\*\* $P < 0.001$  compared with nonresponders. **F**, Incubation in culture did not induce S6c-mediated contraction in these arteries. Femoral arteries after ligation (28 d) contracted in response to endothelin-1 (**G**) but not to S6c (**H**). Data are mean  $\pm$  SEM ( $n = 3$  to 6). ET<sub>A</sub> indicates endothelin<sub>A</sub>; and KPSS, potassium physiological salt solution.

arteries<sup>35</sup>), was abolished by SMET<sub>B</sub> KO (although these functional changes do not necessarily confirm selective SMET<sub>B</sub> deletion). The failure to abolish S6c-induced contraction in trachea was unexpected and suggests either incomplete penetrance of SM22cre-mediated recombination or a role for ET<sub>B</sub> receptors in other cells (eg, epithelium) in mediating tracheal contraction. Detection of the delta band in some ear clip samples may suggest deletion of the floxed gene in germ cells, which is a possible limitation with these mice. However, our F<sup>+</sup>/Cre0x<sup>+</sup>/Cre0 crosses did not produce piebald mice (which inevitably would occur if germ-line recombination takes place). Therefore, the delta band during genotyping can only be explained by the presence of SMC in the ear clip preparations.

Selective deletion of ET<sub>B</sub> from EC increased plasma ET-1<sup>22</sup> because of impaired clearance.<sup>14</sup> In contrast, SMET<sub>B</sub> KO did not alter circulating ET-1, consistent with the proposal that ECET<sub>B</sub> predominantly mediate ET-1 clearance.

Transgenic and pharmacological approaches suggest ET<sub>B</sub> receptors regulate BP. Selective ET<sub>B</sub> receptor antagonism,<sup>20</sup> global ET<sub>B</sub> deletion,<sup>10</sup> and selective ET<sub>B</sub> deletion from the collecting duct<sup>21</sup> all increased ( $\approx 10$ – $13$  mm Hg) BP. Furthermore, ET<sub>B</sub> receptors in peripheral ganglia can influence BP,<sup>36</sup> suggesting that sympathetic activation accounts for ET<sub>B</sub>-induced hypertension.<sup>37</sup> In contrast, BP was not elevated by ECET<sub>B</sub> KO.<sup>22</sup> The small ( $\approx 4$  mm Hg) increase in BP, which persisted in SMET<sub>B</sub> KO mice despite reduced heart rate, suggests that loss of SMET<sub>B</sub> contributes to the increased BP induced by systemic ET<sub>B</sub> antagonism<sup>20</sup> or global ET<sub>B</sub> deletion.<sup>10</sup> However, it requires rejection of our hypothesis that ET<sub>B</sub>-mediated vascular contraction contributes to BP elevation. Indeed, our data support a role for extravascular ET<sub>B</sub> (eg, in the kidney or peripheral ganglia) in regulating BP. This is supported by the demonstration that, as in ECET<sub>B</sub> KO,<sup>22</sup> salt-induced and ET<sub>B</sub> antagonist-induced elevations of BP are unaltered by SMET<sub>B</sub> KO. The mechanism underlying increased BP after SMET<sub>B</sub> KO is not apparent but is unlikely to be a consequence of cre overexpression in SM because this did not alter baseline BP in SMET<sub>A</sub> KO mice.<sup>4</sup> Several possible explanations can be proposed. First, ET<sub>B</sub> in VSMC may contribute to the clearance of ET-1 from tissue where it is preferentially secreted by EC, and where it acts. Therefore, SMET<sub>B</sub> KO may cause ET-1 accumulation in the vascular wall, thus increasing ET-1-mediated vasoconstriction. Second, loss of SMET<sub>B</sub> may upregulate ET<sub>A</sub>-mediated contraction. Third, SMET<sub>B</sub> in the kidney may influence sodium homeostasis. Because SM22 may be expressed in perivascular fat precursors,<sup>36</sup> loss of ET<sub>B</sub> from perivascular fat may have caused developmental changes in vascular function that also contribute to elevated BP, but this has not been established. It is also not clear why basal diastolic blood

pressure is selectively increased in the SMET<sub>B</sub> KO, but this would be worthy of future investigation.

Increased BP in SMET<sub>B</sub> KO mice could not be attributed to vascular dysfunction as, with the exception of responses to S6c, we found no evidence of impaired arterial relaxation or contraction. Weak ET<sub>B</sub>-mediated contraction in arteries is consistent with studies in rats.<sup>35</sup> Preliminary investigations (unpublished data) indicated that S6c-induced contraction of freshly isolated murine arteries (femoral, mesenteric, and carotid) was not increased by NO synthase inhibition or by removal of the endothelium. These results indicate that we are not missing an ET<sub>B</sub>-mediated contraction that has been obscured by ET<sub>B</sub>-mediated relaxation. Induction of ET<sub>B</sub>-mediated contraction after incubation has been attributed to transcriptional regulation and MEK-ERK1/2 signaling.<sup>22,38</sup> Abolition of this response in mesenteric arteries from SMET<sub>B</sub> KO mice indicated that they lack both functional arterial ET<sub>B</sub> receptors and the means to generate new receptors in this tissue.

ET<sub>B</sub> upregulation in SMC, mediating vasoconstriction and proliferation in cardiovascular disease,<sup>18,19</sup> might explain studies reporting similar benefit from mixed ET<sub>A/B</sub> and selective ET<sub>A</sub> antagonism in reducing lesion formation<sup>23,39,40</sup> (despite the protective roles of ET<sub>B</sub> in several tissues, eg, EC and kidney). However, the effectiveness of mixed ET<sub>A/B</sub> and selective ET<sub>A</sub> antagonism is likely to depend on the balance of ET<sub>B</sub> receptor activity in EC and VSMC of an affected artery. Transient upregulation of ET<sub>A</sub> and ET<sub>B</sub> receptors has been demonstrated in arterial lesions.<sup>41</sup> If these ET<sub>B</sub> receptors contribute to lesion formation, then ET<sub>B</sub> antagonism would be desirable. There was, however, no evidence of induced ET<sub>B</sub>-mediated contraction in mouse femoral arteries after ligation. Similar investigations could not be performed after wire injury because these vessels fail to contract ex vivo. It remains possible that ET<sub>B</sub> upregulation occurs in other (eg, carotid) arteries.

Neointimal lesion formation is increased in rescued global ET<sub>B</sub> knockout mice<sup>10</sup> and in (spotted lethal) rats with global deletion of ET<sub>B</sub>,<sup>24</sup> consistent an antiproliferative role for ET<sub>B</sub> receptors. This is supported by demonstrations that ET<sub>B</sub> receptor antagonism increases lesion size,<sup>9,24</sup> with the suggestion that this is because of impaired ET<sub>B</sub>-mediated release of NO from EC. Indeed, increased lesion formation in mice with global ET<sub>B</sub> deletion was partly attributed to impaired EC-derived NO release.<sup>9</sup> In contrast, selective ECET<sub>B</sub> deletion inhibited ET<sub>B</sub>-mediated relaxation<sup>22</sup> but had no effect on arterial lesion formation.<sup>9</sup> These results suggest, therefore, that the protective role of ET<sub>B</sub> receptors is played by non-ECET<sub>B</sub> receptors. The demonstration here that deletion of ET<sub>B</sub> from the SMC does not alter lesion size indicates that, as with the receptors in EC,<sup>9</sup> ET<sub>B</sub> in SMC do not influence neointimal remodeling. This implicates nonvascular ET<sub>B</sub> receptors, for

example, in monocyte-derived macrophages, in the regulation of neointimal proliferation and atherosclerosis.<sup>42</sup>

In conclusion, we have demonstrated that selective ET<sub>B</sub> receptors in SMC may contribute modestly to regulation of BP but have little influence on vascular contraction or neointimal proliferation. These data suggest that any detrimental role of SMET<sub>B</sub> is minor (at least during normal physiology), and, therefore, that selective ET<sub>A</sub> receptor antagonists (which preserve protective EC/renal ET<sub>B</sub> signaling) should be preferred to mixed ET<sub>A/B</sub> antagonists for treatment of vascular disease.

## Perspectives

Generation of mice with selective deletion of ET<sub>B</sub> from SMC indicates that these receptors contribute to the increased BP induced by ET<sub>B</sub> receptor antagonism but do not regulate arterial function or the fibroproliferative response to acute arterial injury. It would be interesting to determine whether ET<sub>B</sub> in SMCs influence other cardiovascular diseases (eg, diabetic complications). Whether the data generated in these animals are replicated in mice with cardiovascular disease (eg, atherosclerosis), or in man, remains to be established. However, these results support the proposal that selective ET<sub>A</sub> receptor antagonists may have advantages over mixed ET<sub>A/B</sub> antagonists for combatting elevated BP or restenosis after revascularization.

## Acknowledgments

A192621 was a gift from AbbVie, United States.

## Sources of Funding

This work was funded by the British Heart Foundation (Project Grant PG/08/068/25461, P.W.F. Hadoke and D.J. Webb; Intermediate Clinical Research Fellowship FS/13/30/29994, N. Dhaun; and Centre of Research Excellence Award) and the Wellcome Trust (107715/Z/15/Z, A.P. Davenport and R.E. Kuc).

## Disclosures

D.J. Webb has provided advice to Abbott, AbbVie, AstraZeneca, Encysive, Pfizer, Retrophin, and Roche in relation to clinical development of endothelin receptor antagonists. K.M. Duthie received a Pfizer Young Investigator Award. N. Dhaun has received research grants from Pfizer.

## References

- Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? *Br J Pharmacol*. 2008;153:1105–1119. doi: 10.1038/sj.bjp.0707516.
- Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. *Pharmacol Rev*. 2016;68:357–418. doi: 10.1124/pr.115.011833.
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988;332:411–415. doi: 10.1038/332411a0.
- Donato AJ, Lesniewski LA, Stuart D, Walker AE, Henson G, Sorensen L, Li D, Kohan DE. Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. *Life Sci*. 2014;118:238–243. doi: 10.1016/j.lfs.2013.12.209.
- Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. *FEBS Lett*. 1988;238:249–252.
- Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. *Hypertension*. 2003;42:997–1003. doi: 10.1161/01.HYP.0000095980.43859.59.
- Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL. Endothelin-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. *Circulation*. 2004;110:2233–2240. doi: 10.1161/01.CIR.0000144462.08345.B9.
- Helset E, Sildnes T, Seljelid R, Konopski ZS. Endothelin-1 stimulates human monocytes *in vitro* to release TNF-alpha, IL-1beta and IL-6. *Mediators Inflamm*. 1993;2:417–422. doi: 10.1155/S0962935193000596.
- Kirkby NS, Duthie KM, Miller E, Kotelevtsev YV, Bagnall AJ, Webb DJ, Hadoke PW. Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. *Cardiovasc Res*. 2012;95:19–28. doi: 10.1093/cvr/cvs137.
- Murakoshi N, Miyauchi T, Kakinuma Y, Ohuchi T, Goto K, Yanagisawa M, Yamaguchi I. Vascular endothelin-B receptor system *in vivo* plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. *Circulation*. 2002;106:1991–1998.
- de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelin-derived relaxing factor. *Proc Natl Acad Sci USA*. 1988;85:9797–9800.
- Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J Clin Invest*. 1993;91:1367–1373. doi: 10.1172/JCI116338.
- Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. *Biochem Biophys Res Commun*. 1994;199:1461–1465. doi: 10.1006/bbrc.1994.1395.
- Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. *Can J Physiol Pharmacol*. 2010;88:644–651. doi: 10.1139/Y10-041.
- Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. *Clin Exp Pharmacol Physiol*. 1999;26:269–271.
- McCulloch KM, Docherty CC, Morecroft I, MacLean MR. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. *Br J Pharmacol*. 1996;119:1125–1130.
- Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. *Br J Pharmacol*. 1997;120:1376–1382. doi: 10.1038/sj.bjp.0701036.
- Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, Malik AB. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. *Am J Physiol*. 1992;263(6 pt 1):C1295–C1301.
- Dimitrijevic I, Edvinsson ML, Chen Q, Malmjö M, Kimblad PO, Edvinsson L. Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. *BMC Cardiovasc Disord*. 2009;9:40. doi: 10.1186/1471-2261-9-40.
- Fryer RM, Rakestraw PA, Banfor PN, Cox BF, Ogenorth TJ, Reinhart GA. Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade. *Am J Physiol Heart Circ Physiol*. 2006;290:H2554–H2559. doi: 10.1152/ajpheart.01221.2005.
- Ge Y, Bagnall AJ, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. *Am J Physiol Renal Physiol*. 2006;291:F1274–F1280. doi: 10.1152/ajprenal.00190.2006.
- Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. *Hypertension*. 2006;48:286–293. doi: 10.1161/01.HYP.0000229907.58470.4c.
- Douglas SA, Loudon C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. *Circ Res*. 1994;75:190–197.
- Kitada K, Yui N, Matsumoto C, Mori T, Ohkita M, Matsumura Y. Inhibition of endothelin ETB receptor system aggravates neointimal

- hyperplasia after balloon injury of rat carotid artery. *J Pharmacol Exp Ther*. 2009;331:998–1004. doi: 10.1124/jpet.109.157065.
25. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, Hammer RE, Herz J, Kuhn M. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. *Proc Natl Acad Sci USA*. 2002;99:7142–7147. doi: 10.1073/pnas.102650499.
  26. Davenport AP, Kuc RE. Radioligand binding assays and quantitative autoradiography of endothelin receptors. *Methods Mol Biol*. 2002;206:45–70. doi: 10.1385/1-59259-289-9:045.
  27. Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. *Life Sci*. 2012;91:716–722. doi: 10.1016/j.lfs.2012.02.003.
  28. Ogenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Geldern TW, Wessale JL, Winn M, Wu-Wong JR. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. *J Pharmacol Exp Ther*. 1996;276:473–481.
  29. Adner M, Uddman E, Cardell LO, Edvinsson L. Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture. *Cardiovasc Res*. 1998;37:254–262.
  30. Kirkby NS, Low L, Seckl JR, Walker BR, Webb DJ, Hadoke PW. Quantitative 3-dimensional imaging of murine neointimal and atherosclerotic lesions by optical projection tomography. *PLoS One*. 2011;6:e16906. doi: 10.1371/journal.pone.0016906.
  31. Rog-Zielinska EA, Thomson A, Kenyon CJ, Brownstein DG, Moran CM, Szumska D, Michailidou Z, Richardson J, Owen E, Watt A, Morrison H, Forrester LM, Bhattacharya S, Holmes MC, Chapman KE. Glucocorticoid receptor is required for foetal heart maturation. *Hum Mol Genet*. 2013;22:3269–3282. doi: 10.1093/hmg/ddt182.
  32. White CI, Jansen MA, McGregor K, Mylonas KJ, Richardson RV, Thomson A, Moran CM, Seckl JR, Walker BR, Chapman KE, Gray GA. Cardiomyocyte and vascular smooth muscle-independent 11 $\beta$ -hydroxysteroid dehydrogenase 1 amplifies infarct expansion, hypertrophy, and the development of heart failure after myocardial infarction in male mice. *Endocrinology*. 2016;157:346–357. doi: 10.1210/en.2015-1630.
  33. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. *Cell*. 1994;79:1267–1276.
  34. Garipey CE, Williams SC, Richardson JA, Hammer RE, Yanagisawa M. Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease. *J Clin Invest*. 1998;102:1092–1101. doi: 10.1172/JCI3702.
  35. Adner M, Geary GG, Edvinsson L. Appearance of contractile endothelin-B receptors in rat mesenteric arterial segments following organ culture. *Acta Physiol Scand*. 1998;163:121–129. doi: 10.1046/j.1365-201X.1998.00369.x.
  36. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, Zhang J, Wu J, Zeng R, Chen YE. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor- $\gamma$  deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. *Circulation*. 2012;126:1067–1078. doi: 10.1161/CIRCULATIONAHA.112.104489.
  37. Fink G, Li M, Lau Y, Osborn J, Watts S. Chronic activation of endothelin B receptors: new model of experimental hypertension. *Hypertension*. 2007;50:512–518. doi: 10.1161/HYPERTENSIONAHA.107.094821.
  38. Zhang W, Li XJ, Zeng X, Shen DY, Liu CQ, Zhang HJ, Xu CB, Li XY. Activation of nuclear factor- $\kappa$ B pathway is responsible for tumor necrosis factor- $\alpha$ -induced up-regulation of endothelin B2 receptor expression in vascular smooth muscle cells *in vitro*. *Toxicol Lett*. 2012;209:107–112. doi: 10.1016/j.toxlet.2011.12.005.
  39. Azuma H, Sato J, Masuda H, Goto M, Tamaoki S, Sugimoto A, Hamasaki H, Yamashita H. ATZ1993, an orally active and novel nonpeptide antagonist for endothelin receptors and inhibition of intimal hyperplasia after balloon denudation of the rabbit carotid artery. *Jpn J Pharmacol*. 1999;81:21–28.
  40. Sanmartín M, Fernández-Ortiz A, Fantidis P, Aragoncillo P, Fernández-Durango R, Rollín R, Alfonso F, Hernández R, Escaned J, Macaya C. Effects of bosentan on neointimal response following coronary angioplasty. *Eur J Clin Invest*. 2003;33:762–768.
  41. Wang X, Douglas SA, Loudon C, Vickery-Clark LM, Feuerstein GZ, Ohlstein EH. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. *Circ Res*. 1996;78:322–328.
  42. Haug C, Schmid-Kotsas A, Zorn U, Schuett S, Gross HJ, Gruenert A, Bachem MG. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. *J Mol Cell Cardiol*. 2001;33:1701–1712. doi: 10.1006/jmcc.2001.1421.

## Novelty and Significance

### What Is New?

- This study describes newly generated mice with selective endothelin<sub>B</sub> (ET<sub>B</sub>) receptor deletion from smooth muscle. This was used to clarify the influence of smooth muscle ET<sub>B</sub> receptors on (1) blood pressure, (2) arterial and venous contraction, and (3) arterial remodeling following injury.

### What Is Relevant?

- Generation of the knockout was necessary because ET<sub>B</sub> receptors in vascular endothelial and smooth muscle cells cannot be distinguished pharmacologically. This work shows that ET<sub>B</sub> receptors in smooth muscle have little influence on arterial function or neointimal remodeling but have a

small suppressive effect on diastolic blood pressure. This is consistent with the proposal that selective endothelin<sub>A</sub> (ET<sub>A</sub>) antagonism would be preferable to mixed ET<sub>A</sub>/ET<sub>B</sub> antagonism for inhibiting arterial remodeling.

### Summary

Selective smooth muscle ET<sub>B</sub> deletion indicated that these receptors play a minor role in regulation of BP but do not affect vascular function or remodeling. This suggests that, beyond endothelial cell ET<sub>B</sub>, ET<sub>B</sub>-dependent regulation of these processes is mediated by receptors in extravascular cells (eg, renal collecting ducts).

## Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling

Eileen Miller, Alicja Czopek, Karolina M. Duthie, Nicholas S. Kirkby, Elisabeth E. Fransen van de Putte, Sibylle Christen, Robert A. Kimmitt, Rebecca Moorhouse, Raphael F.P. Castellan, Yuri V. Kotelevtsev, Rhoda E. Kuc, Anthony P. Davenport, Neeraj Dhaun, David J. Webb and Patrick W.F. Hadoke

*Hypertension*. 2017;69:275-285; originally published online December 27, 2016;  
doi: 10.1161/HYPERTENSIONAHA.115.07031

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Copyright © 2016 American Heart Association, Inc. All rights reserved.  
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/69/2/275>

Free via Open Access

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2016/12/27/HYPERTENSIONAHA.115.07031.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Hypertension* is online at:  
<http://hyper.ahajournals.org/subscriptions/>



SMOOTH MUSCLE ENDOTHELIN B RECEPTORS REGULATE BLOOD PRESSURE  
BUT NOT VASCULAR FUNCTION OR NEOINTIMAL REMODELLING

**Supplementary Information**

Eileen Miller<sup>1</sup>, Alicja Czopek<sup>1</sup>, Karolina M Duthie<sup>1</sup>, Nicholas S Kirkby<sup>1</sup>, Elisabeth E Fransen van de Putte<sup>1</sup>, Sibylle Christen<sup>2</sup>, Robert A. Kimmitt<sup>1</sup>, Rebecca Moorhouse, Raphael FP Castellan<sup>1</sup>, Yuri V Kotelevtsev<sup>3</sup>, Rhoda E Kuc<sup>4</sup>, Anthony P Davenport<sup>4</sup>, Neeraj Dhaun<sup>1</sup>, David J Webb<sup>1</sup> and Patrick WF Hadoke<sup>1</sup>

*<sup>1</sup>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK, <sup>2</sup>University of Basel, Switzerland, Stem Cell Genome Modification Laboratory, <sup>3</sup>Skolkovo Institute of Science and Technology Novaya St. 100, 143025, Skolkovo, Russian Federation, <sup>4</sup>Division of Experimental Medicine & Immunotherapeutics (EMIT), Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ.*

**Short Title:** ET<sub>B</sub> deletion, BP and arterial remodelling

## ***Animals***

Mice with VSMC selective deletion of ET<sub>B</sub> receptors were generated based on a strategy described previously to produce EC ET<sub>B</sub> KO mice<sup>1</sup>. Homozygous (Flox/Flox) ET<sub>B</sub> mice (background: 50% 129/Ola and 50% BKW) were crossed with SM22-Cre transgenic mice and backcrossed to C57Bl/6J for 4-6 generations. As for previous studies<sup>1,2</sup> floxed, Cre-negative littermates (ET<sub>B</sub><sup>f/f</sup>) were used as experimental controls for SM-specific ET<sub>B</sub> deficient mice (SM ET<sub>B</sub> KO). Genotyping to identify wild type and recombined alleles was performed by PCR<sup>1</sup> and the SM22-Cre transgene was detected as described<sup>3</sup>. All mice were given free access to tap water and standard mouse chow. Mice were housed according to United Kingdom Home Office recommendations at 22°C with 12-hour diurnal light/dark cycles. All procedures were performed under the provisions of the Animals Scientific Procedures Act (1986) and with the approval of the local ethics committee.

## ***Autoradiography***

After euthanasia, SM ET<sub>B</sub> KO mice and controls (n=3/group) were rapidly frozen at -70°C, torsos were mounted in a cryostat and consecutive 30µm longitudinal sections were cut to encompass the major thoracic and abdominal organs. Sections were thaw-mounted onto gelatin-coated slides<sup>4</sup> and ligand binding assays performed as described<sup>5</sup>. Briefly, consecutive sections were incubated with 0.25nM of the ET<sub>A</sub> selective ligand [<sup>125</sup>I]PD151242 or 0.25nM of the ET<sub>B</sub> selective ligand [<sup>125</sup>I]BQ2030 (Amersham Bioscience, GE Healthcare, UK). Non-specific binding was determined by co-incubating adjacent sections with the ligand and corresponding excess unlabelled peptide. Slides with calibrated standards were exposed to Kodak MR-1 autoradiography film for 4 days before being developed.

## ***Immunohistochemistry***

Immunohistochemical identification of ET<sub>B</sub> receptors was performed as previously described<sup>6</sup>. Site directed antisera were raised in rabbits to the sequence ET<sub>B</sub>(302-313), as described<sup>7</sup>. Briefly, whole body tissue sections (15 µm) were dried overnight at room temperature and fixed in ice-cold acetone for 10 minutes. Three knock-out and three control mice were examined.

Slides were incubated with 5% non-immunised donkey serum (DS) in phosphate-buffered saline (PBS) for 1 hour at room temperature to block non-specific protein interactions and then incubated overnight at 4 °C with primary rabbit anti-ET<sub>B</sub> (1:50) antiserum and primary goat anti-von Willebrand factor (1:50) PBS/0.1% Tween-20/3% DS. Slides were then washed (3×5 minutes) in cold 1% PBS/0.1% Tween-20 before incubation for 1 hour at room temperature with Alexa Fluor 488 conjugated donkey anti-rabbit (1:200), Alexa Fluor 568 conjugated donkey anti-goat (1:100) secondary antibodies and Hoechst (1:100) diluted in 1% PBS/0.1% Tween-20/3% DS. Tissue sections were washed again (3×5 minutes) in cold 1% PBS/0.1% Tween-20 and mounted with ProLong Gold (Invitrogen). Confocal imaging was performed using a Leica TCS-NT-UV confocal laser-scanning microscope (Leica Microsystems, Heidelberg, Germany).

## ***Ex vivo analysis of ET<sub>B</sub>-mediated contraction***

Functional analyses were performed using isolated mouse trachea, aorta, femoral arteries, and 1<sup>st</sup> order mesenteric arteries and veins, as described<sup>8</sup>. The endothelium was removed from some aortic rings by rubbing the luminal surface with a wire. Some arteries and veins were incubated in serum-free medium (DMEM) for 1-5 days before functional analysis to induce ET<sub>B</sub>-mediated contraction, after the method of Adner *et al.*<sup>9</sup>. Briefly, rings (~2mm in length) of trachea, femoral artery, or mesenteric artery or vein were suspended on two intraluminal

40  $\mu\text{m}$  tungsten wires in a myograph (model 610M Multi-myograph; JP Trading, Aarhus, Denmark) chamber. These rings were equilibrated at their optimum resting force (trachea 2mN; aorta 7.36mN, femoral artery, 8mN; mesenteric artery 3mN; mesenteric vein, 1mN) in physiological salt solution (PSS; 119 mM NaCl, 14.9 mM  $\text{NaHCO}_3$ , 4.7 mM KCl, 1.18 mM  $\text{KH}_2\text{PO}_4$ , 1.17 mM  $\text{MgSO}_4$ , 1.6 mM  $\text{CaCl}_2$ , 0.026 mM EDTA, 5.5 mM glucose), aerated (95%  $\text{O}_2$ , 5%  $\text{CO}_2$ ) and maintained at 37°C. Each ring was then exposed to a high potassium (125mM) PSS (KPSS). Cumulative concentration-response curves were obtained to phenylephrine (PE,  $1 \times 10^{-9}$ - $3 \times 10^{-3}$ M), ET-1 ( $1 \times 10^{-11}$ - $3 \times 10^{-5}$ M), acetylcholine ( $1 \times 10^{-9}$ - $3 \times 10^{-3}$ M) or sarafotoxin 6c (S6c;  $1 \times 10^{-11}$ - $3 \times 10^{-5}$ M), as required. Some rings were incubated with an  $\text{ET}_A$  antagonist (BQ123; 100nM), an  $\text{ET}_B$  antagonist (A192621; 100nM) or a mixture of the two antagonists 20 min before acquiring cumulative concentration-response curves. All responses were measured and recorded with Powerlab software.

### ***Measurement of BP***

Male SM  $\text{ET}_B$  KO mice and age-matched controls (n=8/ group) were caged singly and maintained on standard mouse chow (7 days) before measurement of BP and heart rate using telemetry, as described previously<sup>1</sup>. Briefly, under isoflurane anesthesia, a telemetry catheter was inserted into the left carotid artery and the transmitter device (Data Sciences) secured in the left flank. Mice were allowed to recover and were maintained on standard chow (7 days), high (7.6%) salt diet (7 days), then high salt plus  $\text{ET}_B$  antagonist (SB192621; 30/mg/kg/day in drinking water, 7 days). Systolic and diastolic BP and heart rate were recorded in unrestrained mice (for 5 min every 30 min) as described previously<sup>1</sup> and analyzed using the Powerlab data acquisition system. Average blood pressures over each 5 min period (48 measurements/ day) were used to calculate the 24 h average BP.

### ***Femoral artery injury***

Intra-luminal injury was performed as described<sup>2</sup>. Briefly, under inhaled isoflurane anaesthesia (induction 5%, maintenance 2-3%) a 0.014" diameter straight-sprung angioplasty guide wire was advanced ~1.5cm proximally into the isolated femoral artery through an arteriotomy in the popliteal branch. After withdrawal, the popliteal branch was ligated to allow re-perfusion of the injured femoral artery. Non-denuding injury was achieved by ligation of the right femoral artery at the femero-popliteal bifurcation<sup>2</sup>. Peri-operative analgesia was provided by administration of buprenorphine (0.05mg/kg buprenorphine s.c.; Alstoe Animal Health, UK). Mice were then allowed to recover (28 days) to allow lesion development.

### ***Perfusion fixation***

After the recovery period mice were killed by perfusion fixation. Under terminal anaesthesia (sodium pentobarbital, Ceva Animal Health, UK, 60 mg/kg; i.p.), thoracotomy and transverse sternotomy were performed to allow introduction of a 23-gauge needle into the left ventricle. Phosphate buffered saline containing heparin (Leo Laboratories, UK, 10 U/ml) was administered (6 ml/min) via the left ventricle and an incision was made in the right ventricle to allow perfusate to wash through. Once blood was washed out, 10% neutral buffered formalin (Sigma, UK) was perfused until adequate fixation occurred (indicated by the development of rigidity of the body). Following perfusion fixation, femoral arteries, liver, heart and kidneys were removed. Organs were weighed and all tissues were left in formalin for a further 48h before processing to paraffin for histological assessment.

### ***Optical projection tomography***

Non-destructive 3-dimensional assessment of lesions was performed using optical projection tomography (OPT), as described<sup>10,11</sup>. Briefly, vessels were embedded in agarose and optically cleared in benzyl alcohol/ benzyl benzoate. Intrinsic fluorescent emission was imaged (excitation filter: 425/40 nm; emission filter: 475 nm low pass) using a Bioptonic 3001 tomograph. Data were reconstructed by filtered back projection using NRecon software (Skyscan, Belgium) and volumetric measurements generated by semi-automated tracing of the internal elastic lamina and the neointima distinguished from the lumen using a grey level threshold.

#### ***Histological assessment of neointimal lesions***

Sections (4 µm) were cut from paraffin-embedded femoral arteries at 80 µm intervals with a Leitz 1512 microtome (Leica microsystems, Germany), and mounted onto Superfrost glass slides. Every tenth slide was selected for staining (Shandon Varistain Gemini automated slide stainer) with United States Trichrome, as described<sup>12</sup>. Images were taken using an Axioskop KS300 stage microscope (Carl Zeiss Inc., UK) and a CCD camera (photometrics USA) with a liquid crystal filter (MicroColour, LRI, Inc, USA). Image analysis was performed using MCID basic 7.0 software (Imaging Research, USA). The location of the maximal lesion was determined and serial sections used for compositional analysis, including picro-sirius staining for the quantification of collagen content.

#### ***Immunohistochemistry***

De-waxed and re-hydrated sections were blocked with goat serum before incubation with primary antibodies to  $\alpha$ -smooth muscle actin (1:400; 30 min; Sigma, UK) and Mac2 (1:6000; overnight; Cedarlane, USA). Sections were then washed and incubated with a secondary antibody (goat anti-mouse or goat anti-rat, respectively; 1:400, 30 min; Vector Labs, UK). This was followed by incubation with streptavidin-conjugated horseradish peroxidase Extravidin; 30 min; Sigma, UK). Slides were developed by addition of 3,3-diaminobenzidine (DAB peroxidase staining kit, Vector Lab, UK) for 1 min. Images were taken as before and analysed with Image J software.

#### **References**

1. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. *Hypertension*. 2006;48:286-293.
2. Kirkby NS, Duthie KM, Miller E, Kotelevtsev YV, Bagnall AJ, Webb DJ, Hadoke PWF. Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. *Cardiovasc Res*. 2012;95:19-28.
3. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, Hammer RE, Herz J, Kuhn M. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. *Proc Natl Acad Sci USA*. 2002;99:7142-147.
4. Davenport AP, Kuc RJ. Radioligand binding assays and quantitative autoradiography of endothelin receptors. *Methods Mol Cell Biol*. 2002;206:45-70.
5. Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ. Endothelial cell specific ETB



receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. *Can J Physiol Pharmacol*. 2010;88:644-651.

6. Ling, L, Kuc, RE, Maguire, JJ, Davie, NJ, Webb, DJ, Gibbs, P, Alexander, GJM, Davenport, AP. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ET<sub>B</sub> knockout mice. *Life Sciences*. 2012;91:716-722.
7. Kuc R, Davenport AP Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. *J Cardiovasc Pharmacol* 2004; 44 Suppl 1:S224-226.
8. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnusson SR, Marsh KC, Novosad, EI, von Geldern TW, Wessale GL, Winn M, Wu-Wong JR. Pharmacological characterisation of A-127722: an orally active and highly potent ET(A)-selective receptor antagonist. *J Pharmacol Exp Ther*. 1996;276:473-481.
9. Adner M, Uddmann E, Cardell LO, Edvinsson L. Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture. *Cardiovascular Res*. 1998;37:254-262.
10. Kirkby, NS, Low, L, Riemersma, RA, Seckl, JR, Walker, BR, Webb, DJ, Hadoke, PWF. Quantitative 3-dimensional imaging of murine neointimal and atherosclerotic lesions. *PLoS ONE*. 2011;6 (2):e16906:1-8..
11. Kirkby NS, Low, L, Wu, J, Miller, E, Seckl, JR, Walker, BR, Webb, DJ, Hadoke, PWF Generation and 3-dimensional quantitation of arterial lesions in mice using optical projection tomography. *J Vis Exp*. 2015; 99: 10.3791/50627.
12. Hadoke PWF, Wainwright CL, Wadsworth RM, Butler KD, Giddings M.J. Characterisation of the morphological and functional alterations in rabbit subclavian artery subjected to balloon angioplasty. *Coron Art Dis*. 1995; 6: 403-415.

**Supplementary Table S1.** Deletion of ET<sub>B</sub> from smooth muscle did not alter body or organ weights.

<b>Age &amp; Weights</b>	<b>Wild Type</b>	<b>SMET<sub>B</sub> KO</b>
Age (weeks)	20.0 ± 1.4	20.8 ± 1.6
Body Weight (g)	31.6 ± 0.8	32.1 ± 0.6
Heart (% Body Weight)	0.56 ± 0.03	0.56 ± 0.02
Liver (% Body Weight)	5.08 ± 0.15	4.88 ± 0.18
Right Kidney (% Body Weight)	0.72 ± 0.03	0.74 ± 0.03
Right Kidney (% Body Weight)	0.68 ± 0.02	0.71 ± 0.03
Lung (% Body Weight)	0.54 ± 0.03	0.56 ± 0.02

*Data are mean ± s.e. mean, n=7.*

**Supplementary Table S2.** Impact of endothelial cell removal on function of aorta and femoral arteries from control mice.

Drug	Measurement	Aorta (Intact)	Aorta (Denuded)	Femoral Artery (Intact)	Femoral Artery (Denuded)
PE	N	3	3	3	3
	pD <sub>2</sub>	7.1 ± 0.2	7.3 ± 0.2	5.8 ± 0.1	6.5 ± 0.1*
	E <sub>max</sub> (%)	80.3 ± 5.5	199.8 ± 11.4*	100.3 ± 6.2	94.6 ± 4.5
	E <sub>max</sub> (mN/mm)	3.92 ± 0.34	3.48 ± 0.19	2.35 ± 0.20	1.61 ± 0.14
ACh	N	3	3	3	3
	-logIC <sub>50</sub>	7.4 ± 0.4	7.9 ± 1.0	7.4 ± 0.2	6.5 ± 6.1
	E <sub>max</sub> (%)	62.7 ± 7.1	31.5 ± 7.3	108.6 ± 5.7	19.5 ± 11.8*
ET-1	N	3	3	3	3
	pD <sub>2</sub>	8.5 ± 0.4	8.0 ± 0.2	8.2 ± 0.2	8.4 ± 0.1
	E <sub>max</sub> (%)	53.4 ± 8.4	74.3 ± 4.7	95.2 ± 4.5	89.6 ± 4.2
	E <sub>max</sub> (mN/mm)	1.78 ± 0.42	1.23 ± 0.20	2.51 ± 0.36	2.35 ± 0.46
KPSS	N	4	4	4	4
	E <sub>max</sub> (mN/mm)	2.91 ± 0.58	2.03 ± 0.43	3.21 ± 1.36	2.56 ± 1.23

Data are mean±s.e.mean. ACh, acetylcholine, ET-1, endothelin-1, KPSS, high (125mM) potassium physiological salt solution. PE, phenylephrine. \*P<0.05 compared with intact artery. E<sub>max</sub>, maximum contraction; pD<sub>2</sub>, -log EC<sub>50</sub>.

**Supplementary Table S3** Impact of deletion of ET<sub>B</sub> from vascular smooth muscle on functional responses of femoral arteries.

Drug	Measurement	Wild Type (Intact)	Wild Type (Denuded)	SM ET <sub>B</sub> KO (Intact)	SM ET <sub>B</sub> KO (Denuded)
<b>PE</b>	N	6	7	7	7
	pD <sub>2</sub>	5.7 ± 0.1	6.0 ± 0.1	5.6 ± 0.1	6.1 ± 0.1
	E <sub>max</sub> (%)	88.9 ± 3.2	94.2 ± 3.2	91.9 ± 4.4	102.8 ± 3.8
	E <sub>max</sub> (mN/mm)	3.99 ± 0.35	2.05 ± 0.26	3.48 ± 0.25	2.37 ± 0.20
<b>ACh</b>	N	5	6	6	6
	-logIC <sub>50</sub>	8.0 ± 0.6	6.8 ± 0.4 <sup>†</sup>	7.9 ± 0.5	7.2 ± 0.6*
	E <sub>max</sub> (%)	120.1 ± 10.2	57.8 ± 6.4*	120.9 ± 9.6	22.5 ± 3.2 <sup>‡</sup>
<b>ET-1</b>	N	6	7	7	7
	pD <sub>2</sub>	7.8 ± 0.2	7.8 ± 0.3	7.9 ± 0.2	8.0 ± 0.2
	E <sub>max</sub> (%)	97.4 ± 7.9	112.9 ± 3.5	105.4 ± 5.8	130.3 ± 5.4
	E <sub>max</sub> (mN/mm)	4.03 ± 0.42	2.46 ± 0.40	4.04 ± 0.33	2.99 ± 0.27
<b>KPSS</b>	N	6	7	7	7
	E <sub>max</sub> (mN/mm)	4.44 ± 0.81	1.99 ± 0.64*	3.84 ± 0.52	2.38 ± 0.54

Data are mean±s.e.mean. SM ET<sub>B</sub> KO, selective deletion of the endothelin B receptor from smooth muscle. ACh, acetylcholine, ET-1, endothelin-1, KPSS, high (125mM) potassium physiological salt solution. PE, phenylephrine. \*P<0.05, <sup>†</sup>P<0.01, <sup>‡</sup>P<0.005 compared with intact artery. E<sub>max</sub>, maximum contraction; pD<sub>2</sub>, -log EC<sub>50</sub>.



**Supplementary Table S4.** Impact of endothelin receptor antagonism on endothelin-1-mediated contraction of murine mesenteric arteries.

Measurement	Vehicle	Antagonist		
		ET <sub>A</sub>	ET <sub>B</sub>	ET <sub>A/B</sub>
N	7	3	3	3
pD <sub>2</sub>	8.2±0.5	7.4±0.2*	8.0±0.1	7.0±0.1*
E <sub>max</sub> (mN/mm)	2.4±0.7	2.4±1.3	3.4±0.5	2.3±1.0
E <sub>max</sub> (% KPSS)	105±17	102±21	111±10	75±30

Data are mean±s.e.mean. \*P<0.05 compared with Vehicle. E<sub>max</sub>, maximum contraction; pD<sub>2</sub>, -log EC<sub>50</sub>.

**Supplementary Table S5.** Incubation induces ET<sub>B</sub>-mediated contraction in mouse mesenteric arteries.

Drug	Measurement	Incubation		
		Day 0	Day 1	Day 5
<b>KPSS</b>	N	7	7	3
	E <sub>max</sub> (mN/mm)	2.47±0.80	2.42±0.68	1.40±1.03
<b>PE</b>	N	7	7	3
	pD <sub>2</sub>	5.90±0.25	5.71±0.24	5.65±0.44
	E <sub>max</sub> (mN/mm)	2.33±0.70	2.89±1.30	1.04±1.24
	E <sub>max</sub> (% KPSS)	97.8±15.6	114.1±25.1	111.7±91.7
<b>S6c</b>	N	7	7	3
	pD <sub>2</sub>	---	8.75±0.19	8.73±0.05
	E <sub>max</sub> (mN/mm)	0.13±0.16	1.13±1.08*	0.82±0.60 <sup>†</sup>
	E <sub>max</sub> (% KPSS)	6.4±7.6	40.2±32.6*	94.5±75.4 <sup>†</sup>
<b>ET-1</b>	N	7	5	3
	pD <sub>2</sub>	8.24±0.53	8.50±0.40	8.54±0.25
	E <sub>max</sub> (mN/mm)	2.45±0.73	3.79±0.88*	1.35±1.22*
	E <sub>max</sub> (% KPSS)	105.4±17.8	164.1±16.4*	132.8±87.6

Data are mean±s.e.mean.. ET-1, endothelin-1, KPSS, high (125mM) potassium physiological salt solution, PE, phenylephrine, S6c, sarafotoxin s6c. \*P<0.05 compared with Day 0.

<sup>†</sup>P<0.05 compared with Day 1. E<sub>max</sub>, maximum contraction; pD<sub>2</sub>, -log EC<sub>50</sub>.

**Supplementary Table S6.** Impact of endothelin receptor antagonism on sarafotoxin s6c-mediated contraction of murine mesenteric arteries.

Timepoint	Measurement	Vehicle	Antagonist		
			ET <sub>A</sub>	ET <sub>B</sub>	ET <sub>A/B</sub>
Day 0	N	7	3	3	3
	pD <sub>2</sub>	NC	NC	NC	NC
	E <sub>max</sub> (mN/mm)	0.13±0.16	0.01±0.01	0.03±0.03	0.04±0.04
	E <sub>max</sub> (% KPSS)	6.4±7.6	0.90±1.3	1.0±0.6	1.2±1.2
Day 1	N	7	3	3	3
	pD <sub>2</sub>	8.75±0.19	8.41±0.17*	NC	NC
	E <sub>max</sub> (mN/mm)	1.13±1.08	2.63±0.90	0.01±0.01	0.00±0.01
	E <sub>max</sub> (% KPSS)	40.2±32.6	73.3±17.75	0.7±0.4*	0.4±0.4*

Day 0, fresh arteries; Day 1, 24 h incubation. Data are mean±s.e.mean.. NC, not calculated.


\*P<0.05 compared with Vehicle. E<sub>max</sub>, maximum contraction; pD<sub>2</sub>, -log EC<sub>50</sub>.

**Supplementary Table S7.** The impact of vascular cell selective deletion of murine vascular ET<sub>B</sub> receptors (compared with wild type controls).

Measurement	EC ET <sub>B</sub> KO*	SMC ET <sub>B</sub> KO
Body Weight	NSD <sup>1, 2, 3, 4</sup>	NSD
Organ Weight	NSD <sup>1, 2, 4</sup>	NSD
Plasma [ET-1]		
Basal	Increased <sup>2</sup>	NSD
High salt diet + ET <sub>B</sub> antagonist		NSD
Blood Pressure (basal)		
Basal	NSD <sup>2</sup>	Small (4mmHg) Increase
High salt diet	NSD <sup>2</sup>	Small (4mmHg) Increase
High salt diet + ET <sub>B</sub> antagonist.	NSD <sup>2</sup>	NSD
Heart Rate	NSD <sup>2</sup>	Reduced
Neointimal Proliferation	NSD <sup>1, 4</sup>	NSD
ET <sub>B</sub> -mediated contraction		
Trachea	NSD <sup>1, 2, 4</sup>	Reduced
Mesenteric Vein	N/A	Abolished
Mesenteric Artery	N/A	Induction Abolished
Femoral Artery	N/A	N/A
ACh-mediated relaxation		
Aorta	Impaired <sup>2</sup>	
Femoral Artery	NSD <sup>1, 4</sup>	NSD
ET-1-mediated contraction		
Femoral Artery	NSD <sup>1, 4</sup>	NSD
PE-mediated contraction		
Femoral Artery	NSD <sup>1, 4</sup>	NSD

From previous investigations. <sup>1</sup>Kirkby *et al.*, 2012, <sup>2</sup>Bagnall *et al.*, 2006; <sup>3</sup>Kelland *et al.*, 2010; <sup>4</sup>Kirkby, N.S. PhD Thesis Edinburgh 2009. ACh, acetylcholine; ET-1, endothelin-1; PE, phenylephrine; ET<sub>B</sub>, endothelin B receptor; NSD, No significant difference compared with Wild Type; N/A, not assessed.

## Supplementary Figure S1




### Supplementary Figure S1. Identification of smooth muscle, macrophages and collagen in neointimal lesions.

Compositional analysis of neointimal lesions induced by wire injury in smooth muscle selective ET<sub>B</sub> KO (SMET<sub>B</sub>KO) and wild type mouse femoral arteries showing the presence of immunoreactivity for (a) Smooth muscle actin (brown) and (b) Macrophages (Mac 2; brown). (c) Picrosirius red staining (pink) identified collagen in the neointima and media. Scale bar = 100μm. L, Lumen, NI, neointima.

**Miller *et al.***

## Supplementary Figure S2




**Supplementary Figure S2. Impact of endothelial cell removal on functional responses of murine aorta and femoral artery.**

Aorta (a, b, c) and femoral arteries (d, e, f) from adult male C57Bl/6j mice relaxed in response to acetylcholine (ACh) (a, d) and contracted in response to phenylephrine (PE) (b, e) and endothelin-1 (ET-1) (c, f). Removal of the endothelium abolished ACh-mediated relaxation and substantially increased aortic, but not femoral arterial, contraction to PE. It did not, however, alter ET-1 mediated contraction in aorta or in femoral artery. Symbols represent mean $\pm$ s.e.mean for n= 3 mice. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001.

**Miller *et al.***

## Supplementary Figure S3




**Supplementary Figure S3. Selective deletion of  $ET_B$  from the smooth muscle does not alter femoral artery function.**

Concentration-response curves for (a) phenylephrine (PE), (b) endothelin-1 (ET-1) and (c) acetylcholine (ACh) were generated in femoral arteries from control (FF $^{-/-}$ ) and SM  $ET_B$  knockout (FFSm22Cre) mice. Responses to ACh were obtained following sub-maximal contraction with PE. Deletion of  $ET_B$  had no effect on the responses produced by these agonists. Symbols represent mean  $\pm$  s.e. mean for n=6-7 mice.

**Miller *et al.***




## Supplementary Figure S4



**Supplementary Figure S4. Endothelin-1-mediated contraction of murine mesenteric arteries is mediated by  $ET_A$  receptors.**

In murine mesenteric arteries endothelin-1 (ET-1)-mediated contraction was shifted dramatically to the right by incubation with selective  $ET_A$  (BQ123; 100nM) or mixed  $ET_{A/B}$  antagonism, but selective  $ET_B$  antagonism (A-192621; 100nM) had a much smaller effect. Symbols represent mean $\pm$ s.e.mean, n=3-7. \*P<0.05 compared with Vehicle.

## Supplementary Figure S5




**Supplementary Figure S5. Neointimal lesion formation does not alter functional responses of mouse femoral artery.**

Mouse femoral arteries isolated 28 days after ligation showed unaltered responses to (a) phenylephrine (PE), (b) acetylcholine (ACh) or, (c) sodium nitroprusside (SNP)

Data are mean  $\pm$  s.e. mean, n=3-6.

**Miller *et al.***

## Supplementary Figure S6



Supplementary Figure S6. Schematic summary of the effects of smooth muscle cell specific deletion of the Endothelin B receptor (SM ET<sub>B</sub> KO) in mice.

Miller *et al.*